If you've Googled "finasteride side effects," you've entered a war zone. On one side: clinical trials showing side effect rates barely above placebo. On the other: online forums where men describe devastating sexual dysfunction. Both sides have real data. Both sides have blind spots.
This article isn't here to convince you finasteride is safe or scare you away from it. It's here to give you the actual numbers from the actual studies so you can make your own informed decision. Let's walk through the evidence — all of it.
The Clinical Trial Data: What the Numbers Show
The definitive safety data comes from the Phase III trials that led to FDA approval. Kaufman et al. studied 1,879 men aged 18–41 in three randomized, double-blind, placebo-controlled trials. This is the gold standard study design — neither the patients nor the doctors knew who was getting finasteride and who was getting a sugar pill.
| Side Effect | Finasteride 1mg | Placebo | Difference |
|---|---|---|---|
| Decreased libido | 1.8% | 1.3% | +0.5% |
| Erectile difficulty | 1.3% | 0.7% | +0.6% |
| Ejaculation disorder | 1.2% | 0.7% | +0.5% |
Read that carefully. The difference between finasteride and placebo is roughly half a percentage point for each side effect. That means for every 200 men who take finasteride, about 1 extra man will experience a sexual side effect compared to placebo.
Another important finding from the long-term data: side effect incidence actually decreased over time. By year five, sexual side effect rates had dropped to 0.3% or lower — suggesting that in most cases, the body adapts.
Why does the placebo group have side effects? Because sexual dysfunction is extremely common in the general male population. Roughly 30% of men under 40 report some form of sexual difficulty at any given time. The placebo group's 0.7–1.3% rate reflects the baseline reality that some men will develop these issues regardless of whether they're taking medication.
The Nocebo Effect: When Expectations Create Symptoms
This is where it gets fascinating. In 2007, Dr. Nicola Mondaini at the University of Florence designed an elegant experiment. He gave 120 men with benign prostatic hyperplasia (BPH) finasteride 5mg — five times the hair loss dose — but split them into two groups:
The Mondaini Nocebo Study 2007 • J Sex Med
Group 1 (52 men): Received finasteride described as "an X compound of proven efficacy for BPH." No mention of sexual side effects.
Group 2 (55 men): Received finasteride with the standard disclosure: "it may cause erectile dysfunction, decreased libido, and problems of ejaculation but these are uncommon."
Men who were told about potential sexual side effects reported them at nearly three times the rate of men who weren't told — even though both groups received the exact same drug at the exact same dose.
The breakdown by specific side effect was even more striking:
| Side Effect | Not Informed | Informed |
|---|---|---|
| Erectile dysfunction | 9.6% | 30.9% |
| Decreased libido | 7.7% | 23.6% |
| Ejaculation disorders | 5.7% | 16.3% |
This doesn't mean the side effects aren't real. It means that a significant portion of what men attribute to finasteride is being generated or amplified by their expectations — by reading scary stories online, by the pharmacist's warning label, by the anxiety that comes with taking any medication that touches the hormonal system.
Post-Finasteride Syndrome: Where the Debate Gets Heated
Post-finasteride syndrome (PFS) refers to the claim that some men experience persistent sexual, neurological, and psychological symptoms that continue even after stopping finasteride. It's one of the most contentious topics in dermatology.
What the evidence shows
The Prostate Cancer Prevention Trial (PCPT) — the largest finasteride study ever conducted at 17,313 men over 7 years — found no persistent sexual dysfunction after discontinuation. This is a powerful dataset, though it used 5mg (the prostate dose) rather than 1mg (the hair loss dose).
However, the FDA added persistent sexual side effects to the finasteride label in 2012, and the European Medicines Agency (EMA) acknowledged suicidality signals in 2025. FDA Adverse Event Reporting System (FAERS) data does show increased reporting of persistent symptoms, though increased reporting correlates strongly with increased media coverage and online awareness campaigns rather than necessarily reflecting increased incidence.
The honest take
There is biological plausibility for persistent effects. Finasteride reduces allopregnanolone and other neurosteroids that modulate GABA-A receptors — the same system targeted by anti-anxiety medications. It is physiologically possible for disruptions to this system to linger in some individuals.
At the same time, no large randomized controlled trial has confirmed PFS as a distinct syndrome, and the role of psychological factors (anxiety, nocebo, health anxiety) in amplifying and perpetuating symptoms cannot be ruled out.
Our position: We take these reports seriously and believe affected men deserve medical support and further research. We also believe the available evidence shows that persistent symptoms are rare and that the vast majority of men who use finasteride do not experience lasting side effects. Both things can be true at the same time.
For our complete analysis, read: Post-Finasteride Syndrome: What the Evidence Actually Says in 2026.
Non-Sexual Side Effects
The sexual side effects dominate the conversation, but there are a few other things worth knowing:
- Breast tenderness/gynecomastia: Reported in about 0.5% of men in clinical trials. Usually mild and reversible.
- Depression/mood changes: The EMA flagged a signal for depression and suicidality in 2025. Some observational studies show a small increased risk; others show none. If you have a history of depression, discuss this with your prescriber.
- PSA levels: Finasteride reduces PSA by approximately 50%. If you're getting prostate cancer screening, your doctor needs to know you're on finasteride so they can adjust the interpretation.
Topical Finasteride: A Lower-Risk Alternative?
The Piraccini Phase III trial (458 men, 45 European sites) showed that topical finasteride achieved comparable hair growth results while producing plasma drug levels more than 100 times lower than oral finasteride. Serum DHT reduction was 34.5% with topical vs. 55.6% with oral.
A 2020 Dermatologic Therapy study reported fewer sexual side effects with topical (1.1%) compared to oral (2.7%) over 12 months. If side effect risk is your primary concern, topical finasteride may be worth exploring with your provider.
Interested in Topical Finasteride?
Happy Head specializes in custom-compounded topical formulations prescribed by board-certified dermatologists — including topical finasteride with concentrations tailored to your needs.
Explore Topical Options at Happy Head →How to Minimize Your Risk
If you decide to try finasteride, here are evidence-informed strategies to reduce side effect likelihood:
- Consider topical first. Lower systemic exposure with similar efficacy at the scalp level.
- Start at the standard 1mg dose. There's no evidence that lower doses (0.25mg, 0.5mg) maintain full efficacy, but your doctor may recommend them if you're concerned. See our dose comparison.
- Manage expectations. The Mondaini study shows that anxiety about side effects can literally produce them. Go in informed but not fearful.
- Give it time. Many men who report early side effects find they resolve within the first few months as the body adjusts.
- Have an exit plan. Know that you can stop. DHT returns to normal within 14 days of discontinuation. Finasteride has a short half-life (6–8 hours), unlike dutasteride (4–5 weeks).
Making Your Decision
Here's the framework we recommend:
The Phase III trial data shows a roughly 0.5–0.6% difference between finasteride and placebo for each sexual side effect category. That means approximately 98–99% of men in controlled studies experienced no sexual side effects beyond what the placebo group experienced.
At the same time, finasteride helps 83–99% of men maintain or improve their hair over the long term. The risk-benefit math strongly favors treatment for most men — but "most men" isn't everyone, and you're the one who has to weigh those odds for your own situation.
Talk to a provider. Get your questions answered by someone who can evaluate your specific health profile, not by an anonymous forum post.
Talk to a Licensed Provider
Sesame Care connects you with physicians who can evaluate whether finasteride is appropriate for your situation — transparent pricing, no insurance required.
Find a Provider on Sesame Care →